title: [Perioperative Management of Lung Cancer Patients with atrial fibrillation being treated by antiplatelet or anticoagulant therapy].
abstract: In an aging society, the high incidence of surgery for the patients with ischemic heart disease(IHD)or atrial fibrillation(Af) under antiplatelet or anticoagulant therapy is a great problem. Interruption of antiplatelet or anticoagulant oral agents in the perioperative period may increase the risk of coronary or cerebral events. We retrospectively reviewed the surgical outcomes for lung cancer patients with IHD or Af. We reviewed 135 patients with lung cancer(41~88 years;97 men) who had preoperative oral administration of antiplatelet or anticoagulant drugs for IHD or Af between 2005 and 2012 at 2 centers, and analyzed retrospectively the perioperative medications and complications. IHD, Af and vasospastic angina(VSA) were complicated in 94, 33 and 8 patients, respectively. Drugeluted and bare-metal stents had been placed in 18 and 19 patients. Oral agents were aspirin in 68 patients, ticlopidine in 10 patients, clopidogrel in 15 patients and warfarin in 25 patients. These agents were stopped 2 to 60 days before surgery. Perioperative heparinization was performed in 22 patients. Oral agents were restarted after confirmation of hemostasis and no need for further invasive treatment. The surgical procedures were lobectomy in 88 patients, segmentectomy in 19 and partial resection in 25. There were no hemorrhagic or thromboembolic complications in a perioperative period except 1 case of pulmonary hemorrhage and 1 case of cerebral infarction. No perioperative hospital death was documented. Short-term interruption of antiplatelet or anticoagulant drugs before lung cancer surgery and heparinization was acceptable from the view of perioperative outcomes.
authors.affiliation: Department of Thoracic Surgery, Tenri Hospital, Tenri, Japan.
authors.forename: Shinya
authors.initials: S
authors.lastname: Ishikawa
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Kasai
authors.forename: Natsumi
authors.initials: N
authors.lastname: Matsuura
authors.forename: Shintaro
authors.initials: S
authors.lastname: Tarumi
authors.forename: Jun
authors.initials: J
authors.lastname: Nakano
authors.forename: Masaya
authors.initials: M
authors.lastname: Okuda
authors.forename: Masashi
authors.initials: M
authors.lastname: Goto
authors.forename: Dagu
authors.initials: D
authors.lastname: Ryu
authors.forename: Tetsuhiko
authors.initials: T
authors.lastname: Go
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Yokomise
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects*; D001281:Atrial Fibrillation / Q000150:complications*; D005260:Female; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000150:complications; D019990:Perioperative Care; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D011013:Pneumonectomy; D011183:Postoperative Complications / Q000517:prevention & control; D012189:Retrospective Studies; D012306:Risk; D013997:Time Factors; D016896:Treatment Outcome; D028761:Withholding Treatment
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D006493:Heparin